Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
10.1016/j.freeradbiomed.2020.12.021 2 AkimotoH.NegishiA.OshimaS.WakiyamaH.OkitaM.HoriiN.et al (2020)
Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for two distinct indications: treatment of type 2 diabetes mellitus (Mounjaro) and chronic weight management (Zepbound) in adults with BMI 30 kg/m or 27 kg/m with at least one weight-related comorbidity
130 days: injection site pruritus, ROR 2.478, 95% CI 1.5214.034, P 30 days vs
Karami Fath M, Babakhaniyan K, Zokaei M, Yaghoubian A, Akbari S, Khorsandi M
6 * Moderate risk defined as people with CVD
US$ 24.98
US$ 22.91
US$ 27.30
US$ 20.75
US$ 20.22
